

☐ FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK
OFFICE (MODIFIED)

ATTORNEY'S DOCKET NUMBER

X16397

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)

10/593810

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO.
PCT/US2005/009307

INTERNATIONAL FILING
DATE
17 March 2005 (17.03.2005)

PRIORITY DATE CLAIMED
23 March 2004 (23.03.2004)

TITLE OF INVENTION: ANTI-MYOSTATIN ANTIBODIES

APPLICANT(S) FOR DO/EO/US: Rosamund Carol Smith, Kristine Kay Kikly, Linda O. Tobias, and Bomie Han

Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. ☒ The US has been elected (Article 31).
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form.
 11. ☐ A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 12. to 18. below concern document(s) or information included:**
12. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. ☒ Search Report/Written Opinion (ISA/EP)
 13. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 14. ☐ Assignment has been recorded at reel _____, frame _____.
 15. ☒ A **FIRST** preliminary amendment.
 16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 17. ☒ A Sequence Listing, 1.821 Statement, and diskette.
 18. ☒ A change of power of attorney with attachment.
 18. ☒ Other items or information:
Please amend the first page of the specification by inserting the following cross-reference after the title:
"This is the national phase application, under 35 USC 371, for PCT/US2005/009307, filed 17 March 2005 (17.03.2005), which, claims the benefit, under 35 USC 119(e), of US provisional application 60/555,456, filed 23 March 2004 (23.03.2004); and US provisional application 60/559,621, filed 05 April 2004 (05.04.2004)."

1AP9/Rec'd PCT/PTO 21 SEP 2006

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) <div style="font-size: 1.5em; font-weight: bold;">10/593810</div>		INTERNATIONAL APPLICATION NO. <div style="font-weight: bold;">PCT/US2005/009307</div>		ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold;">X16397</div>	
---	--	--	--	--	--

19.	X	The following fees are submitted:	CALCULATIONS PTO USE ONLY	
(a)		Basic national fee (37 CFR 1.492(a)).....\$300.00	\$ 300.00	
(b)		Examination fee (37 CFR 1.492(c))		
		If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0	\$ 200.00	
		All other situations.....\$200		
(c)		Search fee (37 CFR 1.492(b))		
		If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0	\$ 100.00	
		Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority.....\$100		
		International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB.....\$400		
		All other situations.....\$500		
TOTAL AMOUNT (a + b + c) =			\$ 600.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	8-20=	0	X \$50.00	\$
Independent claims	1-3=	0	X \$200.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$
TOTAL OF ABOVE CALCULATIONS =			\$ 0.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			\$	
SUBTOTAL =			\$ 600.00	
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$	
TOTAL NATIONAL FEE =			\$ 600.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).			\$	
\$40.00 per property +				
TOTAL FEES ENCLOSED =			\$ 600.00	
			Amount to be refunded	\$
			charged	\$

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 05-0840 in the amount of \$600.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, INDIANA 46206-6288 <div style="font-size: 1.2em; font-weight: bold;">21 September 2006</div> <div style="font-size: 0.8em;">Date</div> <div style="font-size: 0.8em;">45.511</div>	 SIGNATURE <div style="border-top: 1px solid black; width: 100%; margin-top: 5px;"></div> MaryAnn Wiskerchen <div style="border-top: 1px solid black; width: 100%; margin-top: 5px;"></div> 317-655-9326 TELEPHONE NUMBER	 <div style="font-size: 1.5em; font-weight: bold;">25885</div> PATENT TRADEMARK OFFICE
---	---	---



10/593810 PCT
09-33-26
LAP/REC'd PCT/PTO 21 SEP 2006

IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicant(s): Rosamund Carol Smith, Kristine Kay Kikly, Linda O. Tobias, and Bomie Han

International Application No.: PCT/US2005/009307

Filed: 17 March 2005 (17.03.2005)

Invention: ANTI-MYOSTATIN ANTIBODIES

Lilly Reference: X16397

Earliest Priority Date: 23 March 2004 (23.03.2004)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO

Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number: EV 393128760 US

Date of Deposit: Sept. 21, 2006

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

QUEEN THOMAS
(Typed or printed name of person mailing paper)

Queen Thomas
(Signature of person mailing paper or fee)

CERTIFICATE UNDER 37 CFR 3.73(b)

Applicant: Rosamund Carol Smith, et al.

Application No.: US Nat'l Phase of PCT/US2005/009307 Filed: 17 March 2005 (17.03.2005)

Entitled: ANTI-MYOSTATIN ANTIBODIES

ELI LILLY AND COMPANY, a CORPORATION
(Name of Assignee) (Type of Assignee, e.g. corporation, partnership, university, government agency, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above.

- ☐ The assignment was recorded in the Patent and Trademark Office at Reel _____, Frame _____.
☒ The assignment is being submitted separately for recordation; a copy of this assignment is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date

September 21, 2006

MaryAnn Wiskerchen
MaryAnn Wiskerchen
Patent Attorney